Antisense oligonucleotides against transcription factor Zif 268 transiently impair excitatory synaptic transmission in the hippocampus without affecting Zif 268 immunoreactivity

Neuroscience Research Communications

Volumn 19, Issue 2, 1996, Pages 125-133

  Szklarczyk, Arkadiusz ^a   Blaszczyk, Janusz ^a   Kaczmarek, Leszek ^a  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

Antisense; Brain; Oligonucleotides; Rat; Side effects

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; PHOSPHOROTHIOIC ACID; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL STRUCTURE; CONTROLLED STUDY; ELECTRIC POTENTIAL; ELECTROPHYSIOLOGY; GRANULAR CELL; HIPPOCAMPUS; IMMUNOREACTIVITY; LONG TERM POTENTIATION; MALE; NERVE CELL; NERVE STIMULATION; NONHUMAN; PATHOLOGY; PROTEIN EXPRESSION; RAT; RNA SEQUENCE; SYNAPTIC TRANSMISSION;

EID: 0029846826     PISSN: 08936609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6769(199609)19:2<125::AID-NRC172>3.0.CO;2-7     Document Type: Article

References (22)

1. Héléne, C. and Toulmé, J.J. (1990) Biochim. Biophys. Acta 1049, 99-125.
2. Wahlestedt, C. (1994) Trends Pharmacol. Sci. 15, 42-46.
3. Szklarczyk, A. and Kaczmarek, L. (1995) J. Neurosci. Meth. 60, 181-187.
4. Szklarczyk, A. and Kaczmarek, L. (1996) Neurochem. International, in press.
5. Abraham, W.C., S.E Mason., J. Demmer, J.M. Williams, C.L Richardson, W.P. Tate, P.A. Lawlor
6. ragunand Dow, M. (1993) Neurosci. 56, 717-727.
7. Neyses, L., J. Nouskas and Vetter, H. (1991) Biochem. Biophys. Res. Commun. 181, 22-27.
8. Sambrook, J., E.F. Fritsch and Maniatis, T. (1989) In: Molecular Cloning: A Laboratory Manual,. Cold Spring Harbor Laboratory Press, 11.23-11.28.
9. Herdegen, T., J.D. Leah, M. Zimmermann and Bravo, R. (1990) Neurosci. Letters 120, 21-24.
10. Chaudhuri, A., J. Matsubara and Cynader, M.S. (1995) Visual Neurosci. 12, 35-50.
11. Hughes P. and Dragunow, M. (1995) Pharmacol. Rev. 47, 133-178.
12. Cole, A.J., D.W Saffen, J.M. Baraban and Worley, P.P. (1989) Nature 340, 474-476.
13. Nikolaev, E., B. Kaminska, W. Tischmeyer, H. Matthies and Kaczmarek, L. (1992) Brain Res. Bull. 28, 479-84
14. Sawai, Y., Y. Sawasaki, and Tsukada, K. (1977) Life Sci. 21, 1351-1356.
15. Neary, J.T., M.P. Rathbone, F. Cattabeni, M.P. Abbracchio and Burnstock, G. (1995) Trends Neurosci. 19, 13-18.
16. Wagner, R.W. (1994) Nature 372, 333-335.
17. Stain CA. (1995) Nature Medicine I, 1119-1121.
18. Linden, D. J., Sheu, F. S., Murakami, K. and Routtenberg, A.(1987) J. Neurosci. 7, 3783-3792.
19. Neuman, L., Kremarik, P. and Pittman Q.,J. (1995) Neuroscience 69, 997-1003.
20. Crook, R.M. (1991) Anti-Cancer Drug Design 6, 609-646.
21. Meeker, R., G. LeGrand, J. Ramirez, T. Smith and Shih, Y.H.. (1995) J. Neuroendocrinol. 7, 419-428.
22. Chiasson, B.J., J.N. Armstrong, M.L. Hooper, P.R. Murphy and Robertson, H.A. (1994) Cell. Mol. Neurobiol. 14, 507-521.